Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ:CING), and Tim Moore, Senior VP of Biotech of Indegene, were recently guests on Benzinga’s All Access.
Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for the relief of the pill burden many people with chronic conditions suffer.
The company has partnered with Indegene, a life sciences commercialization company, to help them commercialize their drug candidate, CTx-1301, a novel ADHD treatment currently in clinical trials.
Watch the full interview here:
Featured photo by Christina Victoria Craft on Unsplash.
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
